4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models.
To report a novel strategy using oligonucleotide aptamers to 4-1BB as an alternate method for costimulation, and show that combinatorial therapy with radiation improves the therapeutic ratio over equivalent monoclonal antibodies.



Subcutaneous 4T1 (mouse mammary carcinoma) tumors were established (approximately 100 mm(3)), and a radiation therapy (RT) dose/fractionation schedule that optimally synergizes with 4-1BB monoclonal antibody (mAb) was identified. Comparable tumor control and animal survival was observed when either 4-1BB antibody or aptamer were combined with RT using models of breast cancer and melanoma (4T1 and B16-F10). Off-target CD8(+) T-cell toxicity was evaluated by quantification of CD8(+) T cells in livers and spleens of treated animals.



When combined with 4-1BB mAb, significant differences in tumor control were observed by varying RT dose and fractionation schedules. Optimal synergy between RT and 4-1BB mAb was observed at 5 Gy × 6. Testing 4-1BB mAb and aptamer independently using the optimal RT (5 Gy × 6 for 4T1/Balb/c and 12 Gy × 1 for B16/C57BL6J mouse models) revealed equivalent tumor control using 4-1BB aptamer and 4-1BB mAb. 4-1BB mAb, but not 4-1BB aptamer-treated animals, exhibited increased lymphocytic liver infiltrates and increased splenic and liver CD8(+) T cells.



Radiation therapy synergizes with 4-1BB mAb, and this effect is dependent on RT dose and fractionation. Tumor control by 4-1BB aptamer is equivalent to 4-1BB mAb when combined with optimal RT dose, without eliciting off-target liver and spleen CD8(+) expansion. 4-1BB aptamer-based costimulation affords a comparable and less toxic strategy to augment RT-mediated tumor control.
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Ana Paula
AP
Benaduce
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Randall
R
Brenneman
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Brett
B
Schrand
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Alan
A
Pollack
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Eli
E
Gilboa
Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida. Electronic address: aishkanian@med.miami.edu.
Adrian
A
Ishkanian
D053330:4-1BB Ligand / Q000037:antagonists & inhibitors* / Q000276:immunology; D000818:Animals; D052157:Aptamers, Nucleotide / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D059248:Chemoradiotherapy / Q000379:methods*; D003131:Combined Modality Therapy / Q000379:methods; D004307:Dose-Response Relationship, Radiation; D005260:Female; D007155:Immunologic Factors / Q000008:administration & dosage; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000473:pathology* / Q000628:therapy*; D011836:Radiation Tolerance / Q000187:drug effects; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D016499:Radioimmunotherapy / Q000379:methods; D011879:Radiotherapy Dosage; D016896:Treatment Outcome
D053330:4-1BB Ligand; D052157:Aptamers, Nucleotide; D007155:Immunologic Factors; D011838:Radiation-Sensitizing Agents